



Dicerna Pharmaceuticals  
Investor Relations Department  
87 Cambridgepark Drive  
Cambridge, MA 02140  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: DRNA

Last Trade:	4.58
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.06 <span style="color: green;">↑</span> (+1.327%)
Day Range	4.19 - 4.68
52-Week Range	2.42 - 6.10
Volume	337,348


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.

[Dicerna Corporate Fact Sheet\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Sep 20, 2017*  
[Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series](#)

*Sep 5, 2017*  
[Dicerna to Present at Rodman & Renshaw 19th Annual Global Investment Conference](#)

*Aug 10, 2017*  
[Dicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update](#)

*Aug 3, 2017*  
[Dicerna to Report Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017](#)

*Jul 17, 2017*  
[Dicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria \(PH\) and Reveals New Therapeutic Target for DCR-PHXC](#)

## Upcoming Events [\[ View all \]](#)

*Sep 27, 2017 11:00 AM ET*  
[LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology](#)

## Financials [\[ View all \]](#)

*Mar 30, 2017*  
[Annual Report \(10-K\)](#)

*May 23, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Aug 10, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 7, 2016*  
[Quarterly Report \(10-Q\)](#)